A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

Chandra, J., Woo, W. P., Finlayson, N., Liu, H. Y., McGrath, M., Ladwa, R., Brauer, M., Xu, Y., Hanson, S., Panizza, B., Frazer, I. H. and Porceddu, S. V.  A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002)…

Read More

c-Jun overexpression in CAR T cells induces exhaustion resistance

Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., Nagaraja, S., Granja, J., de Bourcy, C. F. A., Majzner, R., Satpathy, A. T., Quake, S. R., Monje, M., Chang, H. Y. and Mackall, C. L.  c-Jun overexpression in CAR T cells induces…

Read More

Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy

Hung, C., Xu, X., Li, L., Ma, Y., Jin, Q., Viley, A., Allen, C., Natarajan, P., Shivakumar, R., Peshwa, M. V. and Emens, L. A. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Human Gene Therapy. 2018; 29(5), 614-625. doi:10.1089/hum.2017.080

Read More

High Yield Recovery of Equine Mesenchymal Stem Cells from Umbilical Cord Matrix/Wharton’s Jelly Using a Semi-automated Process

Nazari-Shafti, Bruno, Martinez, Coleman, Alt, McClure (2014). High Yield Recovery of Equine Mesenchymal Stem Cells from Umbilical Cord Matrix/Wharton’s Jelly Using a Semi-automated Process.  In Ivan N. Rich (ed.), Stem Cell Protocols: Springer Protocols, Methods in Molecular Biology, vol. 1235, DOI 10.1007/978-1-4939-1784-6, © Springer Science+Business Media New York 2015

Read More